Literature DB >> 22239492

Cardiovascular aspect of Beta-thalassaemia.

Amar Taksande1, Shakuntala Prabhu, Sumitra Venkatesh.   

Abstract

Beta-thalassaemia major is a genetic blood disorder caused by the reduced synthesis of beta globin chain. The consequences of the resulting chronic anaemia are also common and include growth retardation, bone marrow expansion, extramedular hematopoiesis, splenomegaly, increased intestinal iron absorption, susceptibility to infections, and hypercoagulability. Transfusional iron overload can affect heart function by directly damaging tissue through iron deposition or via iron-mediated effects at other sites. Cardiac dysfunction is common in patients with thalassaemia and is the leading cause of mortality. The main cardiac abnormalities reported in patients with thalassaemia major (TM) and iron overload are left ventricular systolic and diastolic dysfunction, pulmonary hypertension, valvulopathies, arrhythmias and pericarditis. These cardiac abnormalities are a consequence of the general co-morbid conditions in thalassaemia but are closely related to concomitant endocrine deficiencies, hypercoagulability state and inflammatory milieu. Iron's toxicity within cells arises from its capacity to catalyse the production of reactive oxygen species that cause lipid peroxidation and organelle damage, which lead ultimately to cell death and fibrosis. With the introduction of new technologies such as cardiac magnetic resonance T2* , the early detection of cardiac iron overload and associated cardiac dysfunction is now possible, allowing time for reversal through iron chelation therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22239492     DOI: 10.2174/187152512799201172

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  10 in total

1.  Iron overload in Beta thalassaemia major and intermedia patients.

Authors:  Amit Kumar Mishra; Archana Tiwari
Journal:  Maedica (Buchar)       Date:  2013-09

Review 2.  Mechanisms linking red blood cell disorders and cardiovascular diseases.

Authors:  Ioana Mozos
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

3.  Growth pattern in thalassemic children and their correlation with serum ferritin.

Authors:  Vyas Kumar Rathaur; Ayesha Imran; Monika Pathania
Journal:  J Family Med Prim Care       Date:  2020-02-28

4.  Determination of mutations in iron regulating genes of beta thalassemia major patients of Khyber Pakhtunkhwa, Pakistan.

Authors:  Maryam Shah; Lubna Danish; Najeeb U Khan; Fakhar Zaman; Muhammad Ismail; Mehfooz Hussain; Ruqiya Pervaiz; Aqib Iqbal
Journal:  Mol Genet Genomic Med       Date:  2020-06-25       Impact factor: 2.183

5.  Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial.

Authors:  Mohammadreza Rafati; Hossein Karami; Bita Lashtoo-Aghaee; Bahareh Lashtoo-Aghaee; Mojdeh Dabirian; Razieh Avan
Journal:  Caspian J Intern Med       Date:  2022

Review 6.  Oxidative stress in β-thalassaemia and sickle cell disease.

Authors:  S Voskou; M Aslan; P Fanis; M Phylactides; M Kleanthous
Journal:  Redox Biol       Date:  2015-08-01       Impact factor: 11.799

Review 7.  Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area.

Authors:  Mohamad H Qari; Yasser Wali; Muneer H Albagshi; Mohammad Alshahrani; Azzah Alzahrani; Ibrahim A Alhijji; Abdulkareem Almomen; Abdullah Aljefri; Hussain H Al Saeed; Shaker Abdullah; Ahmad Al Rustumani; Khoutir Mahour; Shaker A Mousa
Journal:  Orphanet J Rare Dis       Date:  2013-09-17       Impact factor: 4.123

8.  Cardiorenal syndrome in thalassemia patients.

Authors:  Sorasak Makmettakul; Adisak Tantiworawit; Arintaya Phrommintikul; Pokpong Piriyakhuntorn; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Kanda Fanhchaksai; Pimlak Charoenkwan; Suree Lekawanvijit
Journal:  BMC Nephrol       Date:  2020-08-03       Impact factor: 2.388

9.  Assessment of cardiac and liver iron overload by magnetic resonance imaging in patients with thalassemia major: short-term follow-up.

Authors:  Murat Bayav; Nilgun Isiksalan Ozbulbul; Ozcan Bor
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

Review 10.  Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis.

Authors:  Francesca Vinchi; Emanuela Tolosano
Journal:  Oxid Med Cell Longev       Date:  2013-05-27       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.